Fundz

Fundz Deep Dive

Everything you need to win Entero Therapeutics — in one platform.

Who to reach, what to say, and why now on Entero Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Entero Therapeutics — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Feb 07, 2025over 1 year ago

Contract Type

agreement

Boca RatonBiotechnologyTherapeuticsPharmaceuticalBiopharma

Description

Entero Therapeutics, Inc. has secured a $2 million revolving loan agreement and subsequently appointed three new members to its Board of Directors. As a condition for the loan, Entero replaced three of its Board members with directors designated by the lender.

Company Information

Company

Entero Therapeutics

Location

Boca Raton, Florida, United States

About

Entero Therapeutics, Inc. (Nasdaq: ENTO) is a clinical-stage biopharmaceutical company focused on gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases, including latiglutenase, adrulipase, and capeserod. The company also aims to create a Nasdaq-listed, clinical-stage biopharmaceutical company through the reverse merger with Journey Therapeutics, Inc.

Predictive Intelligence
Strategic

ML-powered predictions for Entero Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.